Patents by Inventor Dennis Panicali
Dennis Panicali has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7771715Abstract: The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect of these costimulatory molecules on the enhanced activation of T cells is demonstrated. The degree of T-cell activation using recombinant vectors containing genes encoding three costimulatory molecules was far greater than the sum of recombinant vector constructs containing one costimulatory molecule and greater than the use of two costimulatory molecules. Results employing the triple costimulatory vectors were most dramatic under conditions of either low levels of first signal or low stimulator to T-cell ratios. This phenomenon was observed with both isolated CD4+ and CD8+ T cells.Type: GrantFiled: March 21, 2007Date of Patent: August 10, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Jeffrey Schlom, James Hodge, Dennis Panicali
-
Publication number: 20090156519Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.Type: ApplicationFiled: December 23, 2004Publication date: June 18, 2009Applicants: AVENTIS PASTEUR, INC., THERION BIOLOGICS, INC.Inventors: Neil Berinstein, James Tartaglia, Mark Parrington, Dennis Panicali, Linda Gritz
-
Publication number: 20090041804Abstract: The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect of these costimulatory molecules on the enhanced activation of T cells is demonstrated. The degree of Tell activation using recombinant vectors containing genes encoding three costimulatory molecules was far greater than the sum of recombinant vector constructs containing one costimulatory molecule and greater than the use of two costimulatory molecules. Results employing the triple costimulatory vectors were most dramatic under conditions of either low levels of first signal or low stimulator to T-cell ratios. This phenomenon was observed with both isolated CD4+ and CD8+ T cells.Type: ApplicationFiled: March 21, 2007Publication date: February 12, 2009Applicant: The Gov. of the USA, as represented by Secretary, Department of Health and Human ServicesInventors: Jeffrey Schlom, James Hodge, Dennis Panicali
-
Publication number: 20070110718Abstract: The present invention is directed to a system for treating individuals at risk of or suffering from breast cancer. The system comprises administering to the individual a recombinant poxvirus, where the poxvirus contains in a foreign nucleic acid encoding at least one breast cancer antigen.Type: ApplicationFiled: November 12, 2004Publication date: May 17, 2007Applicant: Therion Biologics CorporationInventors: Dennis Panicali, Gail Mazzara, Linda Gritz, Jeffrey Schlom, Kwong-Yok Tsang, James Hodge
-
Patent number: 7211432Abstract: The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect of these costimulatory molecules on the enhanced activation of T cells is demonstrated. The degree of T-cell activation using recombinant vectors containing genes encoding three costimulatory molecules was far greater than the sum of recombinant vector constructs containing one costimulatory molecule and greater than the use of two costimulatory molecules. Results employing the triple costimulatory vectors were most dramatic under conditions of either low levels of first signal or low stimulator to T-cell ratios. This phenomenon was observed with both isolated CD4+ and CD8+ T cells.Type: GrantFiled: April 4, 2003Date of Patent: May 1, 2007Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey Schlom, James Hodge, Dennis Panicali
-
Patent number: 7118738Abstract: Recombinant pox viruses capable of expressing an immunogenic fragment of the MUC1 tumor-associated antigen are disclosed. The recombinant viruses can be used as vaccines to prevent the establishment of or treat tumors or pre-tumorous cells expressing the MUC1 tumor-associated antigen. The vaccines can be provided as an admixture comprising: (1) a recombinant pox virus encoding the immunogenic fragment of the MUC1 tumor-associated antigen, and (2) a recombinant pox virus encoding a T-cell co-stimulatory factor. The vaccine admixture can be used, e.g., to prevent establishment of tumors or pre-tumorous cells expressing the MUC1 tumor-associated antigen. The MUC1 specific cytotoxic T-cells can be isolated and expanded and used in a method for treating a host having a tumor expressing MCU1 positive tumor cells.Type: GrantFiled: January 25, 2002Date of Patent: October 10, 2006Assignees: Therion Biologics Corporation, Dana-Farber Cancer Institute, The United States of America as represented by the Department of Health and Human ServicesInventors: Jeffrey Schlom, Judith Kantor, Donald Kufe, Dennis Panicali, Linda Gritz
-
Publication number: 20060159706Abstract: The present invention provides novel insertion sites for introducing DNA into pox vectors.Type: ApplicationFiled: February 20, 2004Publication date: July 20, 2006Inventors: Dennis Panicali, Gail Mazzara, Linda Gritz, Patricia Greenhalgh
-
Publication number: 20060127360Abstract: The present invention relates to peptides, polypeptides, and nucleic acids and the use of the peptide, polypeptide or nucleic acid in preventing and/or treating cancer. In particular, the invention relates to peptides and nucleic acid sequences encoding such peptides for use in diagnosing, treating, or preventing melanoma.Type: ApplicationFiled: September 3, 2004Publication date: June 15, 2006Inventors: Neil Berinstein, Jim Tartaglia, Mark Parrington, Dennis Panicali, Linda Gritz
-
Patent number: 6969609Abstract: The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect of them costimulatory molecules on the enhanced activation of T cells is demonstrated. The degree of T-cell activation using recombinant vectors containing genes encoding three costimulatory molecules was far greater than the sum of recombinant vector constructs containing one costimulatory molecule and greater that the use of two costimulatory molecules. Results employing the triple costimulatory vectors were most dramatic under conditions of either low levels of first signal or low stimulator to T-cell ratios. This phenomenon was observed with both isolated CD4+and CD8+T cells.Type: GrantFiled: November 12, 1999Date of Patent: November 29, 2005Assignee: The United States of America as represented by the Department of Health and Human SerivcesInventors: Jeffrey Schlom, James Hodge, Dennis Panicali
-
Publication number: 20040091995Abstract: Replication-defective recombinant poxvirus encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) are disclosed for use in enriching an immunization site with antigen-presenting cells (APC), for enhancing an immunological response to antigen or immunological epitopes by functioning as a biological adjuvant, for prevention or treatment of neutropenia, and for the treatment of myeloidysplastic syndromes. Compositions comprising a replication-defective recombinant virus encoding GM-CSF alone or in combination with a recombinant virus encoding an antigen and optionally encoding an immunostimulatory molecule are disclosed for enhancing antigen-specific immunological responses, in particular enhancing tumor antigen responses for anti-tumor therapy. Methods for enriching an immunization site with APC and for enhancing immunological responses to an antigen or immunological epitope using replication-defective recombinant poxvirus encoding GM-CSF are disclosed.Type: ApplicationFiled: July 16, 2003Publication date: May 13, 2004Inventors: Jeffrey Schlom, John W. Greiner, Erik Kass, Dennis Panicali
-
Publication number: 20040019195Abstract: The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect of these costimulatory molecules on the enhanced activation of T cells is demonstrated. The degree of T-cell activation using recombinant vectors containing genes encoding three costimulatory molecules was far greater than the sum of recombinant vector constructs containing one costimulatory molecule and greater than the use of two costimulatory molecules. Results employing the triple costimulatory vectors were most dramatic under conditions of either low levels of first signal or low stimulator to T-cell ratios. This phenomenon was observed with both isolated CD4+ and CD8+ T cells.Type: ApplicationFiled: April 4, 2003Publication date: January 29, 2004Inventors: Jeffrey Scholm, James Hodge, Dennis Panicali
-
Publication number: 20030021770Abstract: Recombinant pox viruses capable of expressing an immunogenic fragment of the MUC1 tumor-associated antigen are disclosed. The recombinant viruses can be used as vaccines to prevent the establishment of or treat tumors or pre-tumorous cells expressing the MUC1 tumor-associated antigen. The vaccines can be provided as an admixture comprising: (1) a recombinant pox virus encoding the immunogenic fragment of the MUC1 tumor-associated antigen, and (2) a recombinant pox virus encoding a T-cell co-stimulatory factor. The vaccine admixture can be used, e.g., to prevent establishment of tumors or pre-tumorous cells expressing the MUC1 tumor-associated antigen. The MUC1 specific cytotoxic T-cells can be isolated and expanded and used in a method for treating a host having a tumor expressing MCU1 positive tumor cells.Type: ApplicationFiled: January 25, 2002Publication date: January 30, 2003Applicant: Therion Biologics CorporationInventors: Jeffrey Schlom, Judith Kantor, Donald Kufe, Dennis Panicali, Linda Gritz
-
Patent number: 5972597Abstract: What are disclosed are methods for modifying the genome of vaccinia virus to produce vaccinia mutants, particularly by the introduction into the vaccinia genome of exogenous DNA; modified vaccinia prepared by such methods; certain DNA sequences and unmodified and genetically modified microorganisms involved as intermediates in such methods; and methods for infecting cells and host animals with such vaccinia mutants to provoke the amplification of exogenous DNA and proteins encoded by the exogenous DNA, including antigenic proteins, by said cells and host animals.Type: GrantFiled: May 13, 1995Date of Patent: October 26, 1999Assignee: Health Research IncorporatedInventors: Enzo Paoletti, Dennis Panicali
-
Patent number: 5583028Abstract: Disclosed and claimed are DNA constructs encoding HSV glycoproteins. The constructs are recombinant vaccinia virus, and host cells infected by the recombinant vaccinia virus are also disclosed and claimed.Type: GrantFiled: September 13, 1994Date of Patent: December 10, 1996Assignee: Health Research IncorporatedInventors: Enzo Paoletti, Dennis Panicali
-
Patent number: 5110587Abstract: Vaccines containing vaccinia virus synthetically modified to contain DNA sequences not naturally occurring in vaccinia virus and provoking an immunological response thereto in host animals inoculated with said vaccines.Type: GrantFiled: June 14, 1990Date of Patent: May 5, 1992Assignee: Health Research, IncorporatedInventors: Enzo Paoletti, Dennis Panicali
-
Patent number: 4769330Abstract: What are disclosed are methods for modifying the genome of vaccinia virus to produce vaccinia mutants, particularly by the introduction into the vaccinia genome of exogenous DNA; modified vaccinia prepared by such methods; certain DNA sequences and unmodified and genetically modified microorganisms involved as intermediates in such methods; and methods for infecting cells and host animals with such vaccinia mutants to provoke the amplification of exogenous DNA and proteins encoded by the exogenous DNA, including antigenic proteins, by said cells and host animals.Type: GrantFiled: December 24, 1981Date of Patent: September 6, 1988Assignee: Health Research, IncorporatedInventors: Enzo Paoletti, Dennis Panicali
-
Patent number: 4722848Abstract: What are disclosed are methods for modifying the genome of vaccinia virus to produce vaccinia mutants, particularly by the introduction into the vaccinia genome of exogenous DNA; modified vaccinia prepared by such methods; certain DNA sequences and unmodified and genetically modified microorganisms involved as intermediates in such methods; and methods for infecting cells and host animals with such vaccinia mutants to provoke the amplification of exogenous DNA and proteins encoded by the exogenous DNA, including antigenic proteins, by said cells and host animals.Type: GrantFiled: June 19, 1984Date of Patent: February 2, 1988Assignee: Health Research, IncorporatedInventors: Enzo Paoletti, Dennis Panicali
-
Patent number: 4603112Abstract: What are disclosed are methods for modifying the genome of vaccinia virus to produce vaccinia mutants, particularly by the introduction into the vaccinia genome of exogenous DNA; modified vaccinia prepared by such methods; certain DNA sequences and unmodified and genetically modified microorganisms involved as intermediates in such methods; and methods for infecting cells and host animals with such vaccinia mutants to provoke the amplification of exogenous DNA and proteins encoded by the exogenous DNA, including antigenic proteins, by said cells and host animals.Type: GrantFiled: December 8, 1982Date of Patent: July 29, 1986Assignee: Health Research, IncorporatedInventors: Enzo Paoletti, Dennis Panicali